It sounds like Germany held a "BioPharma" competition to fund drug development. One of the winning groups, NeuroAllianz, is trying to develop therapeutics for neurodegenerative diseases.
Winning Consortium NeuroAllianz in the BioPharma Competition counts on UNIarray Technology
October 9, 2008 - Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips has won the BMBF’s BioPharma competition jointly with consortium “NeuroAllianz”. The twelve project partners will develop therapeutic as well as diagnostic approaches in the field of neurodegenerative diseases from bench to market under the direction of Professor Christa E. Mueller and Professor Alexander Pfeifer. Protagen supports this effort with the proprietary UNIarray® technology platform.
In 2007, the Federal Ministry of Education and Research (BMBF) initiated the BioPharma competition with a funding volume of 100 million Euro. The BioPharma strategy aims to promote biotechnologically produced drugs and to revitalize the German pharmaceutical industry. Three winner consortia were selected out of 37 applications. In the first three years, each consortium will receive 20 million Euro afterwards the remaining 40 million Euro will be allocated. The consortium “NeuroAllianz” counts on the performance of the UNIarray® technology platform to accelerate the development of indication- specific diagnostics.